<DOC>
	<DOCNO>NCT02811978</DOCNO>
	<brief_summary>The purpose phase 3 study determine subcutaneous velcade non-inferior intravenous velcade administer combination low-dose dexamethasone chinese refractory relapse multiple myeloma ( r/rMM ) patient . The study assess overall response rate end 4 cycle velcade dexamethasone administration .</brief_summary>
	<brief_title>Study Subcutaneous Intravenous Velcade Combination With Dexamethasone Chinese Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Have receive least 1 3 prior line therapy multiple myeloma Have Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 The toxicity result previous therapy must resolve stabilized less equal ( &lt; = ) Grade 1 prior drug administration A woman childbearing potential must negative highly sensitive serum ( human chorionic gonadotropin [ hCG ] ) urine pregnancy test screen within 14 day prior Cycle 1 Day 1 Have document evidence progressive disease/disease progression base investigator 's determination response International Myeloma Working Group ( IMWG ) criteria last regimen Received antimyeloma treatment within 2 week 5 pharmacokinetic halflives treatment , whichever longer , date randomization . The exception emergency use short course corticosteroid ( equivalent dexamethasone 40 milligram per day ( mg/day ) maximum 4 day ) treatment . A list antimyeloma treatment correspond pharmacokinetic halflives provide Site Investigational Product Procedures Manual ( IPPM ) Received autologous stem cell transplant ( ASCT ) within 12 week date randomization , participant previously receive allogenic stem cell transplant ( regardless timing ) Plans undergo stem cell transplant prior progression disease study , , participant enrol order reduce disease burden prior transplant Is know infected human immunodeficiency virus ( HIV ) active infection hepatitis B hepatitis C Had myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia clinically significant conduction system abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>